

# THE BIGGEST CANCER BREAKTHROUGH IN 50 YEARS: HOW TO INVEST IN CANCER'S NEWEST THERAPY



PARK AVENUE DIGEST



---

FROM THE DESK OF CHARLES MIZRAHI

For decades, drug companies have been spending billions of dollars and countless hours on researching and developing treatments and cures for cancer.

The reason is easy to understand.

Cancer is the second-leading cause of death.

It kills nearly 600,000 people per year in the U.S. alone.

Another 1.6 million new cases will be diagnosed...

Every year...

A cure for cancer is the holy grail in the health care industry. And the company that does it will immediately become the most valuable company in the world.

Each year, more than 13 million people discover they have cancer. And close to 8 million people die from it each year. It's a disease that keeps taking the lives of our loved ones — a disease that's as old as the pyramids...

## CANCER HAS BEEN AROUND

Cancer dates back to 3000 B.C., to the time of the Great Pyramids of Egypt. It was then that an Egyptian textbook was written. The author of the text, known as the *Edwin Smith Papyrus*, describes eight cases of tumors.



Edwin Smith Papyrus image from U.S. National Library of Medicine.

The author also writes about removing these tumors with fire, basically burning them off. Because there was no way to put the patient to sleep (anesthesia wouldn't be discovered until 1846 in Boston), it was extremely painful. The writing says about the disease, "There's no treatment."

The author also writes about removing these tumors with fire, basically burning them off. Because there was no way to put the patient to sleep (anesthesia wouldn't be discovered until 1846 in Boston), it was extremely painful. The writing says about the disease, "There's no treatment."

Hippocrates, who lived 1,000 years later, is credited with giving cancer its name. He used the Greek word for crab, *carcinos*, to describe it, and it was later translated into Latin.

When Hippocrates first saw cancer, it had finger-like projections and looked like the shape of a crab.

Ancient physicians were at a huge loss. They didn't understand why a person got cancer, and more importantly, they couldn't figure out why it would spread.

Any surgical procedure would end up doing more harm than good. Surgery was extremely risky. Even though a tumor could be cut, poisoned, and burned, it still didn't mean a patient would end up being disease-free.

The patient would have a little more time to live but would still die from the disease spreading.

There was no fighting back — cancer was winning.

It would take until the 1800s and early 1900s for science to be able to punch back.

Cancer wasn't on the ropes just yet, but its legs were starting to wobble...

Since then, hundreds of biotech and pharmaceutical companies across the globe have spent hundreds of billions of dollars and millions of hours on researching, developing, and testing countless cancer treatments and drugs.

Many of these drugs have saved lives. Some have stopped cancer's progression. And others have helped cancer patients live longer.

But there's still no true cure...

## POSSIBLY THE BIGGEST BREAKTHROUGH IN THE FIGHT AGAINST CANCER

But trust me when I say cancer is losing the battle.

And thanks to a new breakthrough developed by a doctor from Israel, we may be closer to completely eliminating cancer than we've ever been before. In fact, I was given the rare opportunity to have a one-on-one sit-down interview with him!

I met Dr. Zelig Eshhar at the Tel Aviv Sourasky Medical Center, the largest acute care facility in Israel, which treats over 400,000 patients per year.



*Dr. Eshhar explaining CAR T cell therapy to me at his office.*

He's come up with a new, radical way of looking at things — a new approach to treating the world's deadliest disease.

He's a pioneer in the fight against cancer.

And now, his breakthrough methodology is causing an amazing revolution in cancer therapy.

It could even replace chemotherapy as the standard treatment within as little as five years!

Dr. Eshhar developed this breakthrough technology while he was a researcher at the Weizmann Institute of Science.


In layman's terms, this is what happens...

Your body has T cells and antibodies, which are parts of your immune system. They both can recognize tumor cells from normal cells.

However, these are not enough to fight cancer cells.

Cancer cells are crafty. They evade and avoid both T cells and antibodies. At the end of the day, the immune system isn't enough to wipe out cancer cells.

Dr. Eshhar came up with a unique way of solving the problem: combining the antibodies with the T cells.



That way, the immune system would be able to gang up on the cancer cells. In his own words: "Two are better than one."

Dr. Eshhar took out T cells from a patient of his. Next, he engineered them to include a molecule that had the cancer-recognition skills of both the antibodies and the T cells.

Once he modified them, he injected the “supercharged” T cells into his patient.

Now, these engineered T cells were able to better recognize cancer cells and were programmed to attack. In studies with animals, the genetically engineered T cells effectively killed cancer cells.

Essentially, they turn your blood into what scientist Dr. Carl June, a well-known researcher into T cell therapies, calls a “true living drug.” Oncologists throughout the entire world are singing its praises.

In fact, multibillion-dollar pharmaceutical juggernauts Novartis and Gilead Sciences just got approval to use this treatment outside of clinical trials. That’s how revolutionarily promising it is.

Dr. Eshhar licensed this technology to Kite Pharma for \$375,000 in 2013.

On August 28, 2017, Gilead Sciences bought Kite for \$12 billion.

There are several companies you should look into. These companies are at the forefront of fighting cancer:

- **Gilead Sciences’ (NASDAQ: GILD)** acquisition of Kite Pharma should give it a high growth platform in CAR T cell therapy.
- **Bristol-Myers Squibb Co. (NYSE: BMY)** has a strong position in lung cancer and melanoma with its drug Opdivo. The drug just received approval for treatment of solid tumor cancer.
- **One of Pfizer’s (NYSE: PFE)** most promising new drugs is Bavencio. The drug received FDA approval for urothelial carcinoma and Merkel cell carcinoma.

## THE SMALL COMPANY SET TO DOMINATE THIS EXPLODING MARKET AND MINT THE NEXT ROUND OF BIOTECH MILLIONAIRES

But there's one smaller, lesser-known firm that stands head and shoulders above the rest... and it's poised to dominate this emerging field.

Even JPMorgan is calling it **"one of the more potentially transformative companies we've come across in some time."**

I believe a stake in this company today could create the kind of wealth that lasts for generations.

So, let me be very blunt about this opportunity — it's that important.

And its stock will reach dizzying levels.

That's why I'm recommending this cancer-fighting company right now.

You don't want to miss out on the opportunity to know the name of this cancer-fighting company and the profits you stand to make from it.

[Click here to access my full report.](#)

Park Avenue Digest © Angel Publishing 2018, 200 Park Ave, New York, NY 10166. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. *Park Avenue Digest* and Angel Publishing do not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.

